DEZHAN HEALTHCARE(SZ:000813)2024-04-24 10:22Revenue and Profitability - Revenue for Q1 2024 was ¥101,250,441.65, a decrease of 25.09% compared to ¥135,160,087.88 in the same period last year[5] - Net loss attributable to shareholders was ¥16,805,072.84, representing a decline of 1,003.80% from a profit of ¥1,859,373.76 in Q1 2023[5] - The net loss for Q1 2024 was ¥21,613,891.55, a decline of 3,809.85% from a profit of ¥582,608.11 in Q1 2023[11] - The company reported a net loss of CNY 5,263,363.13 for Q1 2024, compared to a net loss of CNY 1,568,153.72 in Q1 2023[22] - Operating profit for Q1 2024 was -16,623,167.08 CNY, down from 7,656,637.23 CNY in the same period last year[23] - Total comprehensive income for Q1 2024 was -21,613,891.55 CNY, compared to 582,608.11 CNY in Q1 2023[24] Cash Flow - Cash flow from operating activities decreased by 54.43% to ¥22,723,297.27, down from ¥49,861,633.81 in the previous year[5] - The company experienced a 105.35% decrease in cash flow from investing activities, resulting in a net outflow of ¥20,673,911.95 compared to a net inflow of ¥386,383,653.20 in the previous year[11] - Cash flow from operating activities generated a net amount of 22,723,297.27 CNY, a decrease from 49,861,633.81 CNY in Q1 2023[24] - Cash flow from investing activities resulted in a net outflow of -20,673,911.95 CNY, compared to a net inflow of 386,383,653.20 CNY in the previous year[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥5,357,834,623.56, a slight decrease of 0.39% from ¥5,378,612,557.62 at the end of 2023[5] - The company's total liabilities increased to CNY 150,877,373.16 from CNY 137,145,270.06 at the beginning of the year[20] - Non-current liabilities totaled CNY 37,948,349.21, down from CNY 39,942,766.26 at the beginning of the year[20] - The company’s equity attributable to shareholders was CNY 5,213,981,376.58, a decrease from CNY 5,237,902,679.94 at the beginning of the year[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 55,627[13] - The top 10 shareholders hold a combined 59.27% of the shares, with Shanghai Yueye holding 19.13% and Xinjiang Kaidi holding 18.93%[13] - Meilin Holdings Group has 14.57% of shares, which are currently frozen due to legal issues[15] - Meilin Holdings has been subject to judicial freezing of all its shares, totaling 315,379,600 shares, which is 100% of its holdings[15] Expenses and Income - Total operating costs for Q1 2024 were CNY 106,513,804.78, down 13.2% from CNY 122,728,241.60 year-over-year[22] - Sales expenses decreased by 35.18% to ¥16,885,140.89 from ¥26,048,241.63 in the same period last year[11] - Other income increased by 31.80% to ¥1,049,674.97, primarily due to an increase in government subsidies[11] - Research and development expenses for Q1 2024 were CNY 10,877,646.84, slightly down from CNY 11,907,421.27 in the same period last year[22] Future Expectations - The company expects a net profit attributable to shareholders of between RMB 61 million and RMB 90 million for the fiscal year 2023[15] - The net profit after deducting non-recurring gains and losses is expected to be a loss between RMB 50 million and RMB 95 million[15] Subsidiary Developments - The company completed the capital increase of its subsidiary, Meirui Wana Food and Beverage Co., Ltd., and obtained the new business license[15] - The company established a new subsidiary, Wuhan Weikang Medical Management Co., Ltd., with a total investment of CNY 50 million, where the company holds a 70% stake[16] - The company has completed the transfer of 51% equity of its wholly-owned subsidiary, Beijing Jialin Huikang Pharmaceutical Co., Ltd.[15] Share Capital - The company’s total share capital is 2,241,481,800 shares, with Meilin Holdings directly holding 448,263,156 shares, accounting for 20.00% of the total[15] - The company did not report any net profit from subsidiaries prior to the merger in the current or previous periods[24]